Literature DB >> 8437846

E1A oncogene expression level in sarcoma cells: an independent determinant of cytolytic susceptibility and tumor rejection.

J L Cook1, B A Wilson, L A Wolf, T A Walker.   

Abstract

Ad2/5 E1A oncogene expression induces cytolytic susceptibility of rodent cells to natural killer lymphocytes. To determine whether the requisite thresholds of E1A oncoprotein expression differ for induction of cytolytic susceptibility as compared with other E1A-related activities, sarcoma cells expressing low or normal levels of E1A oncoproteins were compared for differences in morphological transformation, transactivation of viral genes, cytolytic susceptibility and tumorigenicity. Low-level E1A expression transformed sarcoma cells and transactivated the Ad5 E2A gene but did not induce the increased cytolytic susceptibility observed with normal levels of E1A expression. Furthermore, low-level E1A expressers retained the tumorigenicity of parental cells, whereas normal-level expressers were non-tumorigenic in hosts with intact natural killer (NK)-cell responses. In contrast to E1A, E1B oncogene expression caused no changes in morphological, cytolytic or tumorigenic phenotypes in these sarcoma cells. These data define an expression threshold for E1A-induced cytolytic susceptibility and associated NK-cell-dependent tumor rejection. The results suggest that the cellular mechanisms involved in E1A induction of cytolytic susceptibility differ from those involved in E1A-mediated cellular transformation and viral gene transactivation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437846

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells.

Authors:  Tanya A Miura; Han Li; Kristin Morris; Sharon Ryan; Kristine Hembre; James L Cook; John M Routes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection.

Authors:  J L Cook; C K Krantz; B A Routes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  The N-terminal region of the adenovirus type 5 E1A proteins can repress expression of cellular genes via two distinct but overlapping domains.

Authors:  J C Dorsman; B M Hagmeyer; J Veenstra; P Elfferich; N Nabben; A Zantema; A J van der Eb
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Role of the E1A Rb-binding domain in repression of the NF-kappa B-dependent defense against tumor necrosis factor-alpha.

Authors:  James L Cook; Thomas A Walker; G Scott Worthen; Jay R Radke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

5.  Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells.

Authors:  J M Routes; S Ryan
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

Review 6.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

Review 7.  Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

Authors:  Chun-Yu Chen; Brian Hutzen; Mary F Wedekind; Timothy P Cripe
Journal:  Oncolytic Virother       Date:  2018-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.